Organon & Co. (OGN) to Release Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN) will be posting its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Organon & Co. to post earnings of $1.05 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.14. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Down 1.5 %

NYSE:OGN opened at $18.61 on Wednesday. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.79. The stock has a 50-day moving average price of $18.14 and a 200 day moving average price of $15.70. The stock has a market capitalization of $4.79 billion, a P/E ratio of 4.65, a P/E/G ratio of 0.88 and a beta of 0.82.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 6.02%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s dividend payout ratio is currently 28.00%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on OGN shares. Piper Sandler raised their price target on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday. The Goldman Sachs Group raised their price target on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 20th.

Insiders Place Their Bets

In related news, insider Kirke Weaver acquired 2,720 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.17% of the company’s stock.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.